Abstract Library

#4669 Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial

Introduction: Patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) have limited therapeutic options.

Conference:

Presenting Author:

Authors: Capdevila J, Amthauer H, Ansquer C, Deshayes E, Garcia-Carbonero R,

Keywords: radiopharmaceutical therapy, neuroendocrine tumour, [177Lu]Lu-edotreotide, progression-free survival, gastroenteropancreatic,

#4631 Correlations between dosimetry and imaging in patients with neuroendocrine tumour treated with 177Lu-DOTATATE

Introduction: Tumour dose may be an important predictor of clinical response, but estimation of a clinically relevant tumour-absorbed dose without high risk of toxicity is challenging.

Conference:

Presenting Author: Gomez Sanchez D

Authors: Gomez Sanchez D, Ribelles M, Fernandez Iglesias A, Paruta Araez L, Mata E,

Keywords: dosimetry, 177Lu-DOTATATE,

#4533 Receptor radionuclide therapy with 177Lu-DOTATOC (177Luedotreotide or 177Lu-octreotide) in SSTR positive patients: A multicentre, prospective, phase II trial

Introduction: For advanced G1-G2 GEP-NET patients, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE can be recommended. However, there are several SSTR-positive tumours for which PRRT has previously shown efficacy that are not currently covered by the indications for 177Lu-DOTATATE in Italy and, therefore, cannot benefit from it. Less used and studied is the 177Lu-DOTATOC. This is a radiopeptide with excellent safety and efficacy profile in PRRT and certainly not lower than 177Lu-DOTATATE.

Conference:

Presenting Author: Sansovini M

Authors: Sansovini M, Nicolini S, Grassi I, Marini I, Matteucci F,

Keywords: Lu-dotatoc, Radiopharaceutical Therapy Factory, SSTR positive tumour,

#4451 The management of well-differentiated gastroenteropancreatic neuroendocrine tumours in a tertiary centre – The contribution of radionuclide therapy

Introduction: Neuroendocrine tumours represent a heterogenous group of tumours with different locations, whose management is necessary to identify specific parameters that determine the choice of optimal treatment.

Conference:

Presenting Author: Oana Stefania S

Authors: Oana Stefania S, Corin B, Victoria V, Sofia L,

Keywords: GEP-NET, well-differentiated, PRRT, Cromogranine A, Serotonin, RECIST 1.1,

#4052 Transarterial embolisation for liver metastasis in patients with well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors

Introduction: The role of local treatments, including liver-directed transarterial embolization (TAE), in patients (pts) with liver metastasis of advanced grade 3 gastroenteropancreatic neuroendocrine tumor (G3 GEP-NET) is still less understood.

Conference:

Presenting Author: Chen L

Authors: Chen L, Yang D, Yusufu Y, Liu M, Lin Y,

Keywords: gastroenteropancreatic neuroendocrine tumor, transarterial embolization, liver metastasis,